Cuban biotechnology
BioCubaFarma aims at exporting about 5 076 million dollars in the next five years. This Group of Biotechnological and Pharmaceutical Industries was founded in November 2012 and is in charge of the processing of materials by biological agents for producing medicines, equipment and high technological services for improving the population’s health and the generation of exportable goods and services in the current Cuban context. The Group is made up of 38 large companies comprising 21 613 workers. It emerged from the fusion of Quimefa, an enterprise for the production of medicines, and the Biotechnology Scientific Pole, leading institutions in this field in Cuba. According to Dr. Agustin Lage, general director of the Molecular Immunology Center, BioCubaFarma’s main challenges are: - To grow, rely on permanent investment capacities, reach international quality standards (which are not static), diversify exports with a commercial strategy up to par with this purpose, guarantee the constant renovation of products. Disadvantages - Scarce resources, industrial underdevelopment, economic blockade, high migration rates of qualified personnel, deteriorated work and life conditions, objective limitations in the use of TICs and connectivity and internet access. In view of this context, the development strategy by the Cuban biotechnological sector can be summarized...